Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 15/20 | 0.59 |
| ▸ | BRD4 | O60885 | 4/20 | 0.52 |
| ▸ | BRD9 | Q9H8M2 | 4/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | BRD1 | O95696 | 8/20 | 0.44 |
| ▸ | BRPF3 | Q9ULD4 | 3/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | RORA | P35398 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | RORB | Q92753 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL762003 | 0.87 | BRPF1 (0.53) | BRPF1BRD4BRD9CA12CA9 | |
| Flucarbril SCHEMBL2109672 | 0.84 | BRPF1 (0.57) | BRPF1BRD4BRD9CA12CA9 | |
| Flucarbril SCHEMBL30086956 | 0.84 | BRPF1 (0.57) | BRPF1BRD4BRD9CA12CA9 | |
| SCHEMBL422084 | 0.76 | BRPF1 (0.65) | BRPF1BRD4BRD9CA12CA9 | |
| SCHEMBL21112570 | 0.75 | BRPF1 (0.47) | BRPF1BRD4BRD9CA12CA9 | |
| SCHEMBL21112574 | 0.75 | BRPF1 (0.47) | BRPF1BRD4BRD9CA12CA9 | |
| SCHEMBL1771879 | 0.74 | BRPF1 (0.62) | BRPF1BRD4BRD9CA12CA9 | |
| SCHEMBL7085783 | 0.74 | BRPF1 (1.00) | BRPF1BRD4BRD9CA12CA9 | |
| SCHEMBL8556776 | 0.74 | BRPF1 (0.62) | BRPF1BRD4BRD9CA12CA9 | |
| SCHEMBL12745353 | 0.74 | KCNH2 (0.49) | BRPF1KCNH2PGRRORARORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11672799-B2 | 1,4-disubstituted pyridazine quinolne analogs there of and methods for treating SMN-deficiency-related conditions | NOVARTIS AG (CH) | 2023-06-13 | — | — | US | disclosed |
| US-11672799-B2 | 1,4-disubstituted pyridazine quinolne analogs there of and methods for treating SMN-deficiency-related conditions | NOVARTIS AG (CH) | 2023-06-13 | — | — | US | disclosed |
| US-20200239458-A1 | INHIBITORS OF PROTEIN KINASES | ALEXION PHARMACEUTICALS, INC. | 2020-07-30 | — | — | US | disclosed |
| US-20190160062-A1 | 1,4-DISUBSTITUTED PYRIDAZINE QUINOLNE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS AG (CH) | 2019-05-30 | — | — | US | disclosed |
| US-20180186783-A1 | INHIBITORS OF PROTEIN KINASES | ALEXION PHARMACEUTICALS, INC. | 2018-07-05 | — | — | US | disclosed |
| US-20180186783-A1 | INHIBITORS OF PROTEIN KINASES | ALEXION PHARMACEUTICALS, INC. | 2018-07-05 | — | — | US | disclosed |
| US-20180170923-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-9868729-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868729-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9579320-B2 | Inhibitors of syk and JAK protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20120130073-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129867-A1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120130073-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129867-A1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120101275-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-8138339-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8063058-B2 | Inhibitors of syk and JAK protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100048567-A1 | Inhibitors of syk and JAK protein kinases | PORTOLA PHARMACEUTICALS INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-20090318407-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090318407-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318407-A1 | Inhibitors of protein kinases | SYK, BTK, JAK1 | BRPF1 4389/4885BRD4 3725/4885BRD9 3419/4885 |
| US-20180170923-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | FOXM1, SF3B1, SF3B5 | BRPF1 1762/4885BRD4 994/4885BRD9 2119/4885 |
| US-20120129867-A1 | INHIBITORS OF PROTEIN KINASES | SYK, BTK, JAK1 | BRPF1 4389/4885BRD4 3725/4885BRD9 3419/4885 |
| US-20120130073-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | SYK, BTK, JAK1 | BRPF1 4654/4885BRD4 4204/4885BRD9 3627/4885 |
| US-20120101275-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | SYK, BTK, JAK1 | BRPF1 4654/4885BRD4 4204/4885BRD9 3627/4885 |
| US-20200239458-A1 | INHIBITORS OF PROTEIN KINASES | SYK, BTK, JAK1 | BRPF1 4389/4885BRD4 3725/4885BRD9 3419/4885 |
| US-20180186783-A1 | INHIBITORS OF PROTEIN KINASES | SYK, BTK, JAK1 | BRPF1 4389/4885BRD4 3725/4885BRD9 3419/4885 |
| US-20190160062-A1 | 1,4-DISUBSTITUTED PYRIDAZINE QUINOLNE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | SMN1; SMN2, CLN6, PMP22 | BRPF1 2288/4885BRD4 1903/4885BRD9 3564/4885 |
| US-11672799-B2 | 1,4-disubstituted pyridazine quinolne analogs there of and methods for treating SMN-deficiency-related conditions | SMN1; SMN2, CLN6, PMP22 | BRPF1 2288/4885BRD4 1903/4885BRD9 3564/4885 |
| US-20100048567-A1 | Inhibitors of syk and JAK protein kinases | SYK, BTK, JAK1 | BRPF1 4654/4885BRD4 4204/4885BRD9 3627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.